Valeant Pharmaceutical Intl Inc. (NYSE:VRX) has been under immense pressure lately, as the drug maker faced severe allegations which claimed it to be an Enron-like fraud. The situation worsened for Valeant as the political pressure increased on drug prices, and Valeant came under strict scrutiny for increasing drug prices to exorbitant levels.
Valeant’s stock started tumbling down in September when Hillary Clinton brought attention to the practice allegedly being followed by the drug maker, which involved acquiring undervalued and proven drugs and then increasing the price several folds.
